Skip to Content

Aptivus Approval History

FDA Approved: Yes (First approved June 22, 2005)
Brand name: Aptivus
Generic name: tipranavir
Dosage form: Capsules
Company: Boehringer Ingelheim
Treatment for: HIV Infection

Aptivus (tipranavir) is a non-peptidic protease inhibitor which is co-administered with ritonavir for the treatment of HIV Infection.

Development History and FDA Approval Process for Aptivus

DateArticle
Jun 24, 2008Approval New Aptivus (tipranavir) Oral Solution Approved forTreatment-Experienced Pediatric and Adolescent HIV Patients
Oct  5, 2007Approval Aptivus (tipranavir) Capsules Granted Full Approval by the U.S. FDA
Jun 22, 2005Approval FDA Approves Aptivus for HIV Infection
May 19, 2005FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval for Investigational Anti-HIV Drug Tipranavir
Oct 25, 2004Boehringer Ingelheim Submits New Drug Application to U.S. Food and Drug Administration for Tipranavir

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide